Debra K. Czerwinski

10.5k total citations · 3 hit papers
102 papers, 7.6k citations indexed

About

Debra K. Czerwinski is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Debra K. Czerwinski has authored 102 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Immunology, 50 papers in Oncology and 37 papers in Pathology and Forensic Medicine. Recurrent topics in Debra K. Czerwinski's work include Immunotherapy and Immune Responses (48 papers), CAR-T cell therapy research (37 papers) and Lymphoma Diagnosis and Treatment (37 papers). Debra K. Czerwinski is often cited by papers focused on Immunotherapy and Immune Responses (48 papers), CAR-T cell therapy research (37 papers) and Lymphoma Diagnosis and Treatment (37 papers). Debra K. Czerwinski collaborates with scholars based in United States, France and Norway. Debra K. Czerwinski's co-authors include Ronald Levy, Frank J. Hsu, Behnaz Taidi, Edgar G. Engleman, Claudia Benike, Francesco Fagnoni, Idit Sagiv-Barfi, Ash A. Alizadeh, Mark A. Wechser and Izidore S. Lossos and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Debra K. Czerwinski

99 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

1996 1.5k citations Frank J. Hsu, Claudia Benike et al. profile →
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes

2004 708 citations Izidore S. Lossos, Debra K. Czerwinski et al. New England Journal of Medicine profile →
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

2015 352 citations Idit Sagiv-Barfi, Holbrook E. Kohrt et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Debra K. Czerwinski

Since Specialization

Citations

This map shows the geographic impact of Debra K. Czerwinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra K. Czerwinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra K. Czerwinski more than expected).

Fields of papers citing papers by Debra K. Czerwinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra K. Czerwinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra K. Czerwinski. The network helps show where Debra K. Czerwinski may publish in the future.

Co-authorship network of co-authors of Debra K. Czerwinski

This figure shows the co-authorship network connecting the top 25 collaborators of Debra K. Czerwinski. A scholar is included among the top collaborators of Debra K. Czerwinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra K. Czerwinski. Debra K. Czerwinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies 2025 ·Clinical Cancer Research ·Tanaya Shree, Debra K. Czerwinski, Sarah Haebe, Anuja Sathe, Susan M. Grimes, Brock A. Martin, Michael G. Ozawa, Richard T. Hoppe, Hanlee P. Ji, Ronald Levy	1
2	In Vivo mRNA Delivery to the Lung Vascular Endothelium by Dicationic Charge-Altering Releasable Transporters 2025 ·Journal of the American Chemical Society ·(unknown), (unknown), (unknown), Paul J. Hurst, Rebecca L. McClellan, (unknown), Yuan Jia, Salwa Masud, Timothy R. Blake, Adrienne Sallets, Ole Audun Werner Haabeth, Idit Sagiv-Barfi, Debra K. Czerwinski, Marco Herrera‐Barrera, Ronald Levy, Paul A. Wender, Maya E. Kumar, Robert M. Waymouth	0
3	Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging 2025 ·Proceedings of the National Academy of Sciences ·Nisi Zhang, Jai Woong Seo, Elise Robinson, (unknown), James Wang, Yutong Guo, Debra K. Czerwinski, (unknown), Spencer K. Tumbale, Marina N. Raie, Basit L. Jan, (unknown), Adrienne Sallets, Il Minn, Martin G. Pomper, Ronald Levy, Katherine W. Ferrara	1
4	Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors 2023 ·The Journal of Immunology ·Caitlyn L. Miller, Idit Sagiv-Barfi, Patrick Neuhöfer, Debra K. Czerwinski, Carolyn R. Bertozzi, Jennifer R. Cochran, Ronald Levy	2
5	CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity 2022 ·Blood Cancer Discovery ·Tanaya Shree, Vishnu Shankar, (unknown), Debra K. Czerwinski, Joseph G. Schroers‐Martin, (unknown), Sara Beygi, (unknown), (unknown), (unknown), David M. Kurtz, Michael S. Khodadoust, Neel K. Gupta, Lauren S. Maeda, Ranjana H. Advani, Ash A. Alizadeh, Ronald Levy	27
6	A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma 2019 ·Blood ·Tanaya Shree, Michael S. Khodadoust, Debra K. Czerwinski, Matthew J. Frank, Wan Xing Hong, (unknown), Steven Long, Brock A. Martin, Ronald Levy	2
7	In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma 2018 ·Cancer Discovery ·Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, Leo I. Gordon, Jonathan W. Friedberg, Debra K. Czerwinski, Steven Long, Richard T. Hoppe, Robert S. Janssen, Albert F. Candia, Robert L. Coffman, Ronald Levy	142
8	Imaging activated T cells predicts response to cancer vaccines 2018 ·Journal of Clinical Investigation ·Israt S. Alam, Aaron T. Mayer, Idit Sagiv-Barfi, Kezheng Wang, Ophir Vermesh, Debra K. Czerwinski, Emily M. Johnson, Michelle L. James, Ronald Levy, Sanjiv S. Gambhir	107
9	Eradication of Systemic Lymphoma By Local Immunotherapy 2017 ·Blood ·(unknown), Debra K. Czerwinski, Ronald Levy	2
10	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial 2016 ·Blood ·Ronald Levy, Patrick M. Reagan, Jonathan W. Friedberg, Nancy L. Bartlett, Leo I. Gordon, Abraham C.F. Leung, Joanna Peterkin, Biao Xing, Robert L. Coffman, Robert S. Janssen, Albert F. Candia, Michael S. Khodadoust, Matthew J. Frank, Steven Long, Debra K. Czerwinski, Michael P. Chu	15
11	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK breakdown → 2015 ·Proceedings of the National Academy of Sciences ·Idit Sagiv-Barfi, Holbrook E. Kohrt, Debra K. Czerwinski, Patrick P. Ng, Betty Chang, Ronald Levy	352
12	Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies 2013 ·Blood ·Holbrook E. Kohrt, Ariane Thielens, Aurélien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuséri, Cécile Bonnafous, Debra K. Czerwinski, (unknown), Erin Waller, Sophie Ugolini, Éric Vivier, François Romagné, Ronald Levy, Mathieu Bléry, Pascale André	229
13	In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study 2010 ·Journal of Clinical Oncology ·Joshua Brody, Weiyun Z. Ai, Debra K. Czerwinski, James A. Torchia, Mia Levy, Ranjana H. Advani, Youn H. Kim, Richard T. Hoppe, Susan J. Knox, Lewis K. Shin, Irene Wapnir, Robert Tibshirani, Ronald Levy	398
14	Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself 2007 ·The Journal of Immunology ·Jiali Li, Wenru Song, Debra K. Czerwinski, Bindu Varghese, Satoshi Uematsu, Shizuo Akira, Arthur Μ. Krieg, Ronald Levy	98
15	Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes breakdown → 2004 ·New England Journal of Medicine ·Izidore S. Lossos, Debra K. Czerwinski, Ash A. Alizadeh, Mark A. Wechser, Rob Tibshirani, David Botstein, Ronald Levy	708
16	Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. 2001 ·PubMed ·Holden T. Maecker, Susanne Auffermann-Gretzinger, Laurel Nomura, Arcangelo Liso, Debra K. Czerwinski, Ronald Levy	27
17	Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma 2001 ·Biology of Blood and Marrow Transplantation ·Thomas A. Davis, Frank J. Hsu, Clemens B. Caspar, (unknown), Debra K. Czerwinski, (unknown), Behnaz Taidi, Claudia Benike, Edgar G. Engleman, Ronald Levy	27
18	Determination of anti-idiotype antibodies by surface plasmon resonance 1998 ·Journal of Immunological Methods ·Joseph Haimovich, Debra K. Czerwinski, Carmen P. Wong, Ronald Levy	5
19	Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial 1997 ·Blood ·Frank J. Hsu, Clemens B. Caspar, Debra K. Czerwinski, Larry W. Kwak, (unknown), Athanasia Syrengelas, (unknown), Ronald Levy	368
20	Shared Idiotypes Expressed by Human B-Cell Lymphomas 1989 ·New England Journal of Medicine ·Richard A. Miller, (unknown), Michael Samoszuk, (unknown), Sherri Brown, Debra K. Czerwinski, (unknown), Ivor Royston, Ronald Levy	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact